Kainos Medicine, Inc. (KOSDAQ:284620)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
-73.03%
Market Cap 35.56B
Revenue (ttm) 1.17B
Net Income (ttm) -7.78B
Shares Out 32.71M
EPS (ttm) -246.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 883,908
Average Volume 481,084
Open 1,200.00
Previous Close 1,192.00
Day's Range 1,069.00 - 1,245.00
52-Week Range 960.00 - 6,000.00
Beta 1.09
RSI 50.94
Earnings Date May 14, 2026

About Kainos Medicine

Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 284620
Full Company Profile

Financial Performance

In 2025, Kainos Medicine's revenue was 1.17 billion, an increase of 98.46% compared to the previous year's 590.37 million. Losses were -7.78 billion, -36.14% less than in 2024.

Financial Statements

News

There is no news available yet.